-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The National Medical Insurance Bureau issued an announcement on October 16 that in accordance with the "2022 National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan", the National Medical Insurance Bureau organized experts to conduct a comprehensive review of the declared drugs that passed the adjustment form review of the national basic medical insurance, work-related injury insurance and maternity insurance drug catalogue (hereinafter referred to as the 2022 National Medical Insurance Drug Catalogue) in 2022, and at present, the expert review work has been completed
.
.
All reporting enterprises can log on to the "2022 National Medical Insurance Drug Catalogue Adjustment Declaration" module of the national medical insurance service platform to query the expert review results
.
The evaluation results are "proposed to negotiate new contracts", "proposed bidding additions", "proposed negotiation renewals", "proposed simple renewals", etc
.
Among them, if the evaluation result is "new to be negotiated" and "new to be added", it means that the drug has been included in the negotiation/bidding scope of the 2022 national medical insurance drug catalogue and has obtained the negotiation/bidding qualification, which does not mean that the drug has been included in the 2022 national medical insurance drug catalogue
.
.
The evaluation results are "proposed to negotiate new contracts", "proposed bidding additions", "proposed negotiation renewals", "proposed simple renewals", etc
.
Among them, if the evaluation result is "new to be negotiated" and "new to be added", it means that the drug has been included in the negotiation/bidding scope of the 2022 national medical insurance drug catalogue and has obtained the negotiation/bidding qualification, which does not mean that the drug has been included in the 2022 national medical insurance drug catalogue
.